. Author manuscript; available in PMC: 2010 Jul 1.

Published in final edited form as: Anticancer Drugs. 2009 Jul;20(6):444–449. doi: 10.1097/CAD.0b013e32832afc04

Table 1.

IC₅₀ (μmol/l) of FLLL11, FLLL12, and curcumin in human pancreatic cancer cells and normal human cells

	FLLL11	FLLL12	Curcumin
λPANC-1	3.20	3.09	20.35
BXPC-3	0.28	1.31	8.67
MIA-PACA-2	2.52	3.43	11.16
ASPC-1	0.95	2.64	12.40
HPAC	0.50	0.91	15.99
HPDE	0.44	0.26	5.60
Bladder	206.41	886.76	>1000

Pancreatic cancer cells or normal human cells were seeded in 96-well plates (4000λcells/well) in triplicate. The next day, pancreatic caner cells were treated with FLLL11, FLLL12, and curcumin for 72λh. The cell viability was analyzed by MTT assays. IC₅₀ values were calculated using Sigma Plot from two to three independent experiments with each dose of drug in triplicate well.